Real-time Estimate Cboe BZX 03:30:05 2024-07-08 pm EDT 5-day change 1st Jan Change
6.11 USD +4.80% Intraday chart for Bioventus Inc. +8.12% +17.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bioventus Inc.(NasdaqGS:BVS) added to Russell Small Cap Comp Value Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell Small Cap Completeness Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 3000 Value Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 2000 Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 3000E Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 3000 Growth Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 2500 Value Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 2000 Value Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 3000E Growth Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 2000 Growth Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 2000 Dynamic Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 2500 Growth Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell Small Cap Comp Growth Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 2500 Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 3000 Index CI
Bioventus Inc.(NasdaqGS:BVS) added to Russell 3000E Value Index CI
Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 CI
Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024
Bioventus Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024 CI
Earnings Flash (BVS) BIOVENTUS Reports Q1 Revenue $129.5M MT
Earnings Flash (BVS) BIOVENTUS Reports Q1 EPS $0.07 MT
Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating MT
Transcript : Bioventus Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (BVS) BIOVENTUS Posts Q4 Revenue $135.4M MT
Earnings Flash (BVS) BIOVENTUS Reports Q4 EPS $0.07 MT
Chart Bioventus Inc.
More charts
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.83 USD
Average target price
8.5 USD
Spread / Average Target
+45.80%
Consensus
  1. Stock Market
  2. Equities
  3. BVS Stock
  4. News Bioventus Inc.
  5. Earnings Flash (BVS) BIOVENTUS Reports Q3 EPS $0.05